Evidence-first · peptides & research chemicals

A neutral record of what is known.

Mechanisms, trial data, safety signals, and regulatory status for peptides and research chemicals — each claim graded by the strength of the evidence behind it, and reported without persuasion. It reports; it never recommends.

Browse monographs How the grading works

Reports, never recommendsDescribes what the evidence shows. Never tells you to take, dose, or source anything.

Primary sources, honest gradesEvery claim traces to the literature, graded by certainty — including "no human trials" where true.

Sells nothingNo vendors, no affiliates, no commission. Neutrality is the product.

Featured monograph

Investigational

Retatrutide

LY3437943 · GIP / GLP-1 / glucagon triple agonist

A triple-agonist peptide with one fully published Phase 2 trial and a run of Phase 3 results so far reported only as sponsor toplines. A good test of honest grading: promising, and graded conservatively until the data are published.

Read the monograph →

Evidence by endpoint

Weight loss, obesity Limited human

Liver fat / MASLD Limited human

Type 2 diabetes Limited (topline)

Cardiovascular outcomes No outcome data

How the grading works

Strength of evidence, not a verdict

Every claim is graded separately by how much trustworthy human evidence stands behind it. The scale is monochrome on purpose — it measures certainty, never endorsement — and announced-but-unpublished results are flagged and capped.

Robust human — multiple controlled trials, published in full.

Limited human — a single RCT, or small / short / open-label trials.

Preclinical — animal or in-vitro data; no human trials.

(topline) — hatched: announced, not yet peer-reviewed.

Read the full guide and glossary →

Two kinds of page, never blurred

Evidence page